# Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

> **NCT00721409** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 177 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** PD 0332991
- **DRUG:** letrozole
- **DRUG:** letrozole

## Key facts

- **NCT ID:** NCT00721409
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09-15
- **Primary completion:** 2013-11-29
- **Final completion:** 2017-12-20
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2019-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00721409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00721409, "Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00721409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*